CIGNA and EMD Serono Team to Fight Multiple Sclerosis

CIGNA CI and EMD Serono, Inc. have entered into the nation's first outcomes-based contract for a specialty medication, aimed at improving the health of people with multiple sclerosis (MS).

The CIGNA and EMD Serono contract is designed to help people with multiple sclerosis prevent significant relapses. Results will be measured in part by the percentage of hospitalization and emergency room visits that are avoided through the use of EMD Serono's multiple sclerosis drug, Rebif® (interferon beta-1a). Because each relapse may lead to additional irreversible neurologic damage in people with relapsing multiple sclerosis, another goal is to help delay the progression of the disease and potential disability through CIGNA's integrated services.